$100+ Billion spent on myriad of acquisitions across Pharma and Biotech industries in H1 2018
Lloyd Price
JULY 5, 2018
For many biotech companies, mergers and acquisitions have become a cornerstone in building a robust pipeline that can ensure positive growth for years to come. 2017 was considered to be a lean year for M&A in biotech. Although 2017 was slow for M&A activity, analysts have predicted 2018 could be a return to a spending frenzy.
40 
Let's personalize your content